112901-68-5|Amifostine trihydrate|S-(2-((3-aminopropyl)amino)ethyl) O,O-dihydrogen phosphorothioate trihydrate|-范德生物科技公司

Amifostine trihydrate

NMR下载 COA and HPLC MSDS下载
names：
S-(2-((3-aminopropyl)amino)ethyl) O,O-dihydrogen phosphorothioate trihydrate
CAS号：
112901-68-5
MDL Number：
MF(分子式)： C5H21N2O6PS MW(分子量)： 268.26
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Amifostine trihydrate
英文别名	WR2721; WR-2721; WR 2721; YM08310; YM-08310; YM 08310; Aminopropylaminoethylthiophosphoric Acid; ethiofos; gammaphos. US brand name Ethyol. Abbreviation APAETP.
CAS号	112901-68-5
SMILES	OP(O)(SCCNCCCN)=O.[H]O[H].[H]O[H].[H]O[H]
Inchi	InChI=1S/C5H15N2O3PS.3H2O/c6-2-1-3-7-4-5-12-11(8,9)10;;;/h7H,1-6H2,(H2,8,9,10);3*1H2
InchiKey	TXQPXJKRNHJWAX-UHFFFAOYSA-N
分子式 Formula	C5H21N2O6PS
分子量 Molecular Weight	268.26
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	white solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Amifostine trihydrate(CAS:112901-68-5 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Amifostine is a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Duval M, Daniel SJ. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity. J Otolaryngol Head Neck Surg. 2012 Oct;41(5):309-15. Review. PubMed PMID: 23092832.

[2]Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Jan;21(1):357-64. doi: 10.1007/s00520-012-1613-6. Epub 2012 Oct 3. Review. PubMed PMID: 23052919.

[3] Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1778-85. doi: 10.1007/s00259-009-1368-6. Epub 2010 Feb 4. Review. PubMed PMID: 20130857.

[4] Dang YH, Li W, Yang B, Zhu HL, Huang Y. [Mechanism and problem of amifostine in treating myelodysplastic syndromes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Dec;17(6):1597-601. Review. Chinese. PubMed PMID: 20030955.

[5] Ma C, Xie J, Chen Q, Wang G, Zuo S. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007956. doi: 10.1002/14651858.CD007956.pub2. Review. PubMed PMID: 19821441.

6: Marcu LG. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. Eur J Cancer Care (Engl). 2009 Mar;18(2):116-23. doi: 10.1111/j.1365-2354.2008.01032.x. Review. PubMed PMID: 19267726.7: Mell LK, Movsas B. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1341-50. doi: 10.1517/17425255.4.10.1341 . Review. PubMed PMID: 18798703.8: Praetorius NP, Mandal TK. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. J Pharm Pharmacol. 2008 Jul;60(7):809-15. doi: 10.1211/jpp.60.7.0001. Review. PubMed PMID: 18549666.9: Kouloulias VE, Kouvaris JR. Cytoprotective efficacy of amifostine against radiation- induced rectal toxicity: objective and subjective grading scales for radiomucositis. Molecules. 2008 Apr 18;13(4):892-903. Review. PubMed PMID: 18463591.10: Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007 Jun;12(6):738-47. Review. PubMed PMID: 17602063.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开